KISUNLA™ Referral Form





Fax Completed Form To:

Phone:

		PATIEN	NT INFORMATION			
Patient Name:		1			Date of Birth:	
Referral Date: Updated Order Order Renewal						
Address: City/State/Zip:						
Home Phone:		Cell Phone:			Work Phone:	
Secondary Contact:		Height:	Weight:		☐ Male ☐ Female	
Allergies:						
Current Medications:						
Other Medical Conditions or Additional Comments:						
Medical History Related to IV Insertion (e.g. lymph nodes or mastectomy):						
DIAGNOSIS						
Patient Diagnosis & ICD-10: G30.0 - Alzheimer's disease with early onset G30.1 - Alzheimer's disease with late onset G30.8 - Other Alzheimer's disease						
Prescriber must indicate the following requirements have been met to confirm diagnosis & that Patient has evidence of AD neuropathology & has been assessed for baseline ARIA risk via MRI:						
☐ Amyloid pathology confirmed via: ☐ Amyloid PET Scan - OR -☐ CSF Analysis - OR -☐ Blood plasma Result: ☐ Amyloid positive ☐ Amyloid negative (<i>Kisunla</i> [™] is not a treatment option for this Patient, if checked)					Date:	
☐ Recent MRI obtained prior to initiating Kisunla™ (including FLAIR and T2/GRE or SWI) to assess ARIA risk☐ Prescriber has verified that this Patient does not have evidence of prior ARIA-H					Date:	
☐ Completion of cognitive assessment type: ☐ MMSE ☐ MoCA ☐ CDR ☐ Other: Score:					Date:	
☐ Completion of functional assessment type: ☐ FAQ ☐ FAST ☐ Other:					Date:	
□ Results for ApoE Testing					Date:	
☐ Completion of CMS approved CED registry (only required for Patients with Medicare) ClinicalTrials.gov Registry Number: NCT Submission Number (if applicable):					CED Submission Date:	
Note: MRIs must be obtained prior to initial infusion to assess ARIA risk. During treatment, conduct an ARIA monitoring MRI before Infusions 2, 3, 4 and 7 and if symptoms consistent with ARIA occur.						
PROVIDER INFORMATION						
Physician Name:		Lic.#:		DEA #:		
Practice Name:				NPI#:		
Address:				City/State/Zi	ip:	
Office Contact:		Phone:		7	Fax:	
Supervisory Physician (if applicable):						
PLEASE ATTACH						
□ Patient demographics & front/back copy of all insurance cards (prescription & medical) □ Recent office visit notes, history & physical, lab & pertinent procedure results □ Letter of medical necessity if drug dosing or indication is outside of FDA guidelines						
☐ Current medication list & list of prior medications tried and failed (with dates) ☐ Line access documentation/verification if applicable						
NURSING & LAB ORDERS						
Nurse Orders: Nurse to provide assessment, teaching, lab draws, medication administration and vascular access device insertion and/or management per physician orders.						
Flush Orders: NaCl 0.9% - 5-10mL flush pre and post infusion and as needed Heparin - 10units/mLOR 10units/mL - 3-5mL flush after post-infusion NS flush if indicated to maintain line Lab Orders:						
PRESCRIPTION ORDERS						
Anaphylaxis Kit:						
(Check all that apply) Diphenhydramine mg IV as needed NS Hydration 500 ml IV over 30 minutes as needed Other						
Pre-Medications: □ Acetaminophenmg P0minutes prior to infusion □ Solu-Medrolmg IVminutes prior to infusion [Check all that apply) □ Diphenhydraminemg □ P0OR □ IVminutes prior to infusion □ Other						
Supply Orders: All supplies for vascular access line care, drug administration kit(s), pump, and IV pole will be provided as necessary						
PRODUCT		PRESC	RIPTION INFORMA	ATION		REFILLS
Is this a first dose?						
	□ Induction: 700mg IV infusion via □ gravityOR□ pump over 30 minutes every 4 weeks x 3 doses					NONE
☐ KISUNLA	□ Maintenance: 1400mg IV infusion via □ gravity OR □ pump over 30 minutes every 4 weeks					
	If missed dose, administer the same dose as soon as possible and continue every 4 weeks. Obtain MRI prior to 2nd, 3rd, 4th, and 7th infusions. MRI results must be performed and cleared by MD to proceed to next infusion.					
	Ubtain MRI prior to 2nd, 3rd, 4th, and 7	th infusions. MRI results	s must be performed and clea	red by MD to	proceed to next infusion.	116::-
☐ OTHER						NONE
By signing this for	rm and utilizing our services, you are author	izing Amerita to serve as y	your prior authorization design	ated agent in	dealing with medical and prescription insurance com	panies.

Prescriber's Signature
Dispense as Written

© 2024 Amerita Inc. All rights reserved.

AME MOS_KISUNLA REFER 12.24

Print Name Date

Prescriber's Signature Substitution Permitted Print Name

Date

TED ACCREDIT